Original Article
Chronopharmacodynamics of gefitinib-based anti-cancer effect in Lewis tumor-bearing mice

Bin Zhang1*, Yanqin Cheng2*, Xiujie Fang3, Qing Lu2, Jiao Liu2, Guoxin Liu2, Peipei Wang2, Liang Liu2, Pingping Lin2, Mingchun Li2

1Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Medicinal Plant Development (IMPLAD), Beijing 100193, China; 2Department of Pharmacy, The 401st Hospital of Chinese People’s Liberation Army, Qingdao, Shandong 266071, China; 3Beijing Dongcheng Community Health Service Center, Beijing 100010, China. *Equal contributors.

Received December 10, 2015; Accepted March 19, 2016; Epub August 15, 2016; Published August 30, 2016

Abstract: Gefitinib is a tyrosine kinase inhibitor in the fight against NSCLC by inhibiting intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor. To explore the influence of different dosing times on the efficacy and toxicities of gefitinib and the underlying mechanism, a mouse model of Lewis lung carcinoma was established in C57BL/6 mice. The tumor and skin tissues were observed with scanning electron microscopy. In addition, the levels of IL-6 and TNF-α, phosphorylation level of EGFR and ERK1/2, and mRNA expressions of EGFR, ABCG2, and MMP-9 were determined by ELISA, Western-blot and qRT-PCR technique, respectively. The present study found administration of gefitinib at 8:00 and 4:00 significantly inhibited the tumor growth, and IL-6 and TNF-α levels were higher between 16:00 and 24:00 than at 8:00. Meanwhile, the level of pEGFR and pERK1/2 was higher at 16:00 and 20:00. The cells apoptosis induced by gefitinib administered at 8:00 was more aggravating compared with administration at 16:00. These findings indicate that efficacy and toxicities of gefitinib vary with the time of day of administration. The molecular mechanism of action may be related to dynamic activity of EGFR-RAS-RAF-ERK1/2 pathway. Accordingly, the time of gefitinib administration should be taken into consideration in clinic.

Keywords: Gefitinib, NSCLC, EGFR, circadian rhythm, tumor, lung cancer

Introduction
Lung cancer, which leads to 1.38 million annual deaths worldwide, is the most common cause of cancer mortality in men and the second most common cause in women [1]. The 5-year survival rate of this disease for all stages is only 15% [2]. There into, non-small-cell lung cancer (NSCLC) accounts for 80% of all the types of lung cancer. Although most NSCLC patients can benefit from chemotherapy, the platinum-based first-line therapy can only bring about median survival times of 8 to 11 months, with 1- and 2-year survival rates being 35-40% and 10-20%, respectively [3, 4]. Furthermore, poor prognosis and disease progression are inevitable, and simultaneously severe cytotoxicities confine these drugs’ utilization. Therefore, it is extremely urgent to search for a more effective method to treat NSCLC.

In the past decades, great progress has been made in the exploration of signal transduction pathways. Epidermal growth factor receptor (EGFR) is a member of erbB family of transmembrane receptors tyrosine kinase, which is over-expressed in many solid tumors, including head and neck, non-small cell lung and prostate cancers [5]. Activation of EGFR by ligand binding can promote tumor proliferation, angiogenesis, invasion and metastasis [6]. Therefore, inhibiting EGFR pathways might be a promising strategy in the treatment of advanced NSCLC. In all of EGFR-targeted agents, gefitinib (IRESSA), an orally administered small molecular targeted drug, is a typical representative. As a targeted therapeutic agent, gefitinib has demonstrated its clinical advantage in the treatment of advanced NSCLC patients who have previously received platinum-based chemotherapy, especially females, never-smokers, and those with adenocarcinoma histology [7, 8]. The mechanism of this drug is that it can reversibly bind the ATP pocket in the EGFR intracellular tyrosine kinase domain and inhibit its tyrosine kinase [9].
Biological rhythms, existing naturally from unicellular organisms to complex mammalians, synchronize organisms’ physiological, biochemical, metabolic and behavioral processes with changes in the external environment, to guarantee the organisms to accommodate, anticipate, and respond to the changes effectively [10]. Based on the biological rhythms, it has been put forward that cancer might be caused by circadian-related disorders [11]. Moreover, recent researches have interpreted that many behaviors of both normal cells and tumor cells in mammals show a characteristic 24-hour circadian rhythm of their growth, proliferation, DNA synthesis, and secretion activities [12-16]. As most chemotherapeutic agents not only inhibit the malignant cells but impair normal healthy cells, the therapeutic effect of the drugs should be weighed against their toxicities. Hence, optimizing the dosing time of the drugs according to the circadian rhythm plays a critical role in maximizing their anti-tumor efficacy and in decreasing their adverse reactions. The efficacy of some antimetabolites, such as platinum drugs (cisplatin, carboplatin, and oxaliplatin), 5-fluorouracil, and doxorubicin, has displayed notable circadian rhythm [17-19]. The basis for these drugs might be the differences in the biological rhythmicity of proliferation and DNA synthesis between normal healthy cells and malignant cells. However, as a small molecular targeted agent, gefitinib is completely distinct from the above drugs in the anticancer mechanism. What’s more, no relevant researches have been reported in the field of chronotherapy. So identifying its circadian rhythm is meaningful to the cancer patients and will help to achieve better chronopharmacotherapy for NSCLC treatment.

The purpose of this study was to investigate the influence of gefitinib on the inhibition of tumor growth at different times in mice and the underlying mechanism. We aim to find a proper time for chemotherapy to provide the reference to the clinical treatment.

Materials and methods

Mice, cells and reagents

C57BL/6 female mice (aged 5 weeks 18-20 g) were purchased from Vital River Laboratory Animal Technology Co. Ltd (Beijing, China). The mice were housed in common animal lab in groups of 5 per cage under standardized light-dark cycle conditions (lights (501 ×) on from 7:00 to 19:00) at a room temperature of 24±1°C and a humidity of 60±10% with food and water available ad libitum. The mice were accommodated to the light/dark cycle for one week before the experiments. All animal experiments were conducted in accordance with the Bioethics Committee guidelines in the 401st Hospital of Chinese People’s Liberation Army.

The Lewis lung carcinoma cells (ATCC, CRL-1642) were bought from Beijing Chuanglian North Carolina Biotechnology Research Institute. The cells were then cultured with Dulbecco’s modified Eagle’s medium (HyClone laboratories Inc USA) containing 10% fetal bovine serum, 1% penicillin, and 1% streptomycin (HyClone laboratories Inc USA) in a 37°C humidified incubator with 5% CO₂ atmosphere. A total of 0.2 ml of 1 × 10⁶ viable tumor cells was injected into the left hind footpad of each mouse. One week later, evident implanted tumors were observed.

Gefitinib (AstraZeneca UK Limited) was provided by the 401st Hospital of Chinese People’s Liberation Army. The tablets were stored at room temperature and dissolved in distilled water with 5% sodium carboxymethylcellulose before application. To observe its therapeutical effect, the drug was given to tumor-bearing mice via intragastric administration (100 mg/kg).

Experiment design

The tumor-bearing mice were randomly allocated into 7 groups (n = 10), including the Model group, experimental groups 8:00, 12:00, 16:00, 20:00, 24:00, and 4:00. The mice in the 6 experimental groups were given via gavage a single dose of gefitinib (100 mg/kg), and those in the Model group were treated with the same volume of 5% sodium carboxymethylcellulose before application. To observe its therapeutical effect, the drug was given to tumor-bearing mice via intragastric administration (100 mg/kg).

Tumor volume assessment

The length and width diameters of the tumors of each mouse were measured with vernier caliper every three days during the experiments. The tumor volume was calculated as shown in Eq 1 [20].
Tumor volume (cm$^3$) = $A \times B^2/2$ (Eq 1)

where A is the length diameter and B is the width one (centimeter).

**Tumor weight and tumor inhibition rate**

After three weeks’ treatment, the mice were killed by cervical dislocation. Their tumors were pelt off in sterile conditions and weighed. The tumor inhibition rate was calculated as shown in Eq 2 [21],

\[
\text{Tumor inhibition rate (\%) } = \frac{\text{Average tumor weight of control group} - \text{Average tumor weight of treatment group}}{\text{Average tumor weight of control group}} \times 100%
\]

(Eq 2)

**ELISA analysis of TNF-α and IL-6 levels**

The blood samples were collected from the eye socket vein of the mice after three weeks’ treatment with the drug. TNF-α and IL-6 levels in the blood were determined by ELISA kit (Biolegend Inc.) according to the manufacturer’s recommendations. The absorbance of the samples was read on the microplate reader (BIO-TEK Elx-800/808) at 450 nm.

**Scanning electron microscopy (SEM)**

In preparation for SEM, the tumor and skin tissues were cut with a razor blade into many small blocks. Afterwards the block specimens were completely rinsed in a 0.1 M phosphate buffer solution (PBS), fixed in 2.5% glutaraldehyde for a few hours, and postfixed in 1% OsO$_4$ in PBS. Next, they were dehydrated in a graded series of ethanol solutions, immersed in isoamyl acetate, and critical-point-dried in CO$_2$. Finally, they were ion-sputtered with palladium and observed via a scanning electron microscopy (Hitachi Ltd. S-4800, Japan).

**qRT-PCR analysis**

The expression levels of EGFR, ABCG2 (ATP-binding cassette sub-family G member 2), MMP-9 (matrix metalloproteinase-9), and GAPDH were determined by qRT-PCR technique. The total mRNA was extracted with RNAiso Plus (Takara Biotechnology (Dalian) Co., Ltd.) according to the manufacturer’s instruction. cDNA was synthesized from 2 μl total RNA using PrimeScript$^\text{TM}$ RT reagent Kit (Takara Biotechnology (Dalian) Co., Ltd.). The qRT-PCR analyses were performed using TL989 Real Time Quantitative PCR (Xi’an Tianlong Science and technology Co., Ltd). The primers of the above genes were designed and synthesized by Takara Biotechnology (Dalian) Co., Ltd based on the principles for prime design by UCSC. The primers sequences and cycling conditions of each gene were displayed in Table 1.

**Protein extraction and western blot**

Frozen tumor tissues were transferred into mortar, and then crushed with pestle to homogenize until powdery after the adding of liquid nitrogen. According to the amount of tissue powder, appropriate ice-cold lysis buffer (50 mM Tris-HCl, pH 7.8, 150 mM NaCl, 5 mM EDTA, 0.5% Nonidet P-40, 2 mM PMSF, 1 mM Na$_3$VO$_4$) was added, and then the homogenous tissue was cultured on ice for 30 min. After the removal of the insoluble materials by centrifugation at 12,000 g for 10 min at 4°C, the protein concentrations in tumor mass lysates were determined using a bicinchoninic acid protein assay kit (CWBio, China), and the resulting supernatants were mixed with an 1/5 volume of 5 x sample buffer and boiled at 95°C for 5 min. Equal amounts of proteins (10 μl/well) were separated using 10% SDS-polyacrylamide gels electrophoresis and then transferred to PVDF membrane (Millipore, US). Subsequently, the membranes were incubated overnight at 4°C with antibodies against β-actin, total EGFR (tEGFR), phospho-EGFR (pEGFR), total ERK1/2 (tERK1/2), phospho-ERK1/2, bax and bcl-2 (monoclonal rabbit anti-mouse antibodies 1:1000; Cell Signaling Technology, US) at 4°C. Then the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (Rabbit IgG, 1:6000; Cell Signaling Technology, US). The images from the immunoreactive membrane were digitized. Protein band intensities were quantified using NIH Image software.

**TUNEL assay**

DNA fragmentation in situ was detected by TUNEL assay according to the kit instructions (Roche, Germany). 4',6-diamidino-2-phenylindole (DAPI) was included in the kit as DNA fragments could be stained by TUNEL specifically and produced green fluorescence, while DAPI could combine with complete DNA and debris and produced blue fluorescence. Briefly, tissue sections were fixed with 4% paraformaldehyde at room temperature, and then rinsed with PBS for 5 min and incubated in a permeabilization solution (1% Triton X-100 in 0.1% sodium
citrate) for 2 min on ice. The TUNEL reaction mixture was added and the samples were incubated for 1 h at 37°C humidified atmospheres (5% CO₂) in the dark and then dyed with 1 μg/ml of DAPI for 15 min. After rinsing with PBS, samples were analyzed under a fluorescence microscope using an excitation wavelength in the range of 450-500 nm and detection in the range 515-565 nm. The apoptotic rate was indicated by percentage of the TUNEL-positive cell number against the total cell number (DAPI-positive) within the same area from five random selected fields in each treatment.

**Statistical analysis**

All statistical analyses were accomplished using SPSS 19.0 (SPSS Inc., Chicago, IL). All quantitative data were expressed as Mean ± SD and analyzed using one-way ANOVA and LSD (Least-significant difference), while the comparison between rates was carried out by χ² test. A value of P < 0.05 was set as statistically significant.

**Results**

**Influence of gefitinib dosing times on tumor volume**

Figure 1A shows the influence of dosing times on the gefitinib inhibition on tumor growth. The tumor growth displayed significant differences among groups in which gefitinib administered at different time points. Three weeks later, the minimum average tumor volume was detected in group 8:00. The volume was smaller than the Model, groups 16:00 (P < 0.01, LSD). The tumor in group 4:00 also showed a small volume, but was bigger than group 8:00 on average (P > 0.05).

**Influence of gefitinib dosing times on tumor weight and tumor inhibition rate**

The tumor inhibition rate of each group is displayed in Table 2, which exhibits marked differences among different gefitinib groups (χ² = 36.00, P = 0.000). Group 8:00 showed the maximum tumor inhibition rate, and it was significantly higher than those of groups 16:00, 20:00, and 24:00 (P < 0.05, χ² test). However, the tumor inhibition rate was insignificantly different among groups 16:00, 20:00, and 24:00 (P > 0.05).

**Influence of gefitinib dosing times on TNF-α and IL-6 levels in blood**

Both IL-6 and TNF-α production in the blood were significantly augmented in the treatment groups when compared with those in the Model group (Figure 2A, 2B). Treatment with gefitinib at 8:00 can relatively normalize the IL-6 production. The secretion of IL-6 was markedly increased in the mice which were given gefitinib at the other times, particularly at 16:00 and 20:00 (Figure 2A). Also, TNF-α level in group

<table>
<thead>
<tr>
<th>Genes</th>
<th>Prime sequence</th>
<th>Accession NO.</th>
<th>Cycling conditions</th>
<th>Number of cycles</th>
</tr>
</thead>
</table>
| EGFR  | F: GTAGTGAGCTGAGGGGCTTTACTGG | NM_207655.2 | 1. 30 s
2. 5 s | Process 2 with 40 cycles |
|       | R: TCAGGGATGGATAACCGGTTAGG | | 30 s | 60 s |
| ABCG2 | F: ACGACTGTTTGAGCTCAAGCAG | NM_011920.3 | 1. 30 s
2. 5 s | Process 2 with 35 cycles |
|       | R: AAGATGGAATAACCGGAGCTGATG | | 30 s | 30 s |
| MMP-9 | F: GCCCTGAATCAGCACGACAG | NM_013599.2 | 1. 30 s
2. 5 s | Process 2 with 40 cycles |
|       | R: TTGAAACTCACACGCAAGAAG | | 30 s | 60 s |
| GAPDH | F: TGTCTCCGTGGAGCTCTGA | NM_008084.2 | 1. 30 s
2. 5 s | Process 2 with 40 cycles |
|       | R: TTGCTGTTGAAGTCGAGAAG | | 30 s | 60 s |
Observation of tumor and skin tissues by SEM

As is shown in Figure 1B, obvious differences in the appearance of Lewis lung carcinoma cell surfaces were observed, including their number, distribution, and morphology of microvilli. The biggest number of the tumor cells was observed in the Model group (Figure 1Bg), and their arrangement was extremely tight. No conspicuous deformation was noticed. The distribution of cells in Figure 1Ba was excessively irregular, with large amounts of deformation of cells. The surfaces of these cells were highly unsmooth. Although the number of the tumor cells in Figure 1Bf exceeded that in Figure 1Ba, 8:00 was significantly lower than that in groups 16:00 (P < 0.05, Figure 2B).

Table 2. Tumor weight and tumor inhibition rate in mice from various groups

<table>
<thead>
<tr>
<th>Groups</th>
<th>Tumor weight (g)</th>
<th>Tumor inhibition rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>3.04±0.62</td>
<td>44.12%</td>
</tr>
<tr>
<td>12:00</td>
<td>3.62±1.74</td>
<td>33.46%</td>
</tr>
<tr>
<td>16:00</td>
<td>4.67±2.04</td>
<td>14.15%</td>
</tr>
<tr>
<td>20:00</td>
<td>4.22±1.17</td>
<td>22.43%</td>
</tr>
<tr>
<td>24:00</td>
<td>4.43±1.02</td>
<td>18.57%</td>
</tr>
<tr>
<td>4:00</td>
<td>3.35±1.37</td>
<td>38.42%</td>
</tr>
<tr>
<td>Model</td>
<td>5.44±1.57</td>
<td></td>
</tr>
</tbody>
</table>

8:00 was significantly lower than that in groups 16:00 (P < 0.05, Figure 2B).

Figure 1. The antitumor effect of gefitinib treated at 8:00 was enhanced compared to those were given at other time points. The tumor volume was determined after 3 weeks treatment (A) and Lewis lung carcinoma cells were observed by SEM (B). Pictures Ba-g were from groups 8:00, 12:00, 16:00, 20:00, and 24:00 and Model group, respectively. The arrow in picture pointed to abnormal deformation of cells, with fibrotic substances covered. *P < 0.05 compared to group 16:00, #P < 0.01 as compared to Model group (LSD).
microvilli on their surface were much more than those in Figure 1Bb-e.

There was significant distinction in the skin tissues among the seven groups (Figure 2C). The cell surface in Figure 2Ca was a little rougher than that in Figure 2Cg, in which the cell surface was extremely smooth and bright. The situations were even worse in Figure 2Cb-e, where some fibrosis appeared. The most serious was found in Figure 2Cc, in which the skin cells were completely covered by the fibrous substances. The results imply that the impairment by gefitinib to the normal skin might be less when administered at 8:00.

Gene expressions of EGFR, ABCG2, MMP-9 in tumor bearing mice

As shown in Figure 3A, the mRNA expression of EGFR in various groups exhibited insignificant differences ($P > 0.05$) for the over-expression of EGFR in all of the tumor-bearing mice.

ABCG2, the gene related to the transportation of gefitinib, was determined. There were no obvious distinction among groups 8:00, 12:00, and 16:00 ($P > 0.05$, Figure 3B). The mRNA expression of ABCG2 in group 20:00 was upregulated by twice when compared with that in group 8:00 ($P < 0.05$, LSD).

To observe the influence of gefitinib given at different times on the tumor metastasis, the mRNA expression of MMP-9 was measured because it was found over-expressed in many advanced NSCLC patients [22-25]. As shown in Figure 3C, the mRNA expression of MMP-9 in group 20:00 was increased by 3.20 and 3.32 folds when compared to groups 8:00 and 4:00, respectively ($P < 0.05$, LSD).
Figure 3. Relative quantification of mRNA expression of EGFR, ABCG2, and MMP-9 in tumor masses. A. The mRNA expression of EGFR in the tumors from various groups. B. The mRNA expression of ABCG2 in the tumors from various groups. C. The mRNA expression of MMP-9 in the tumors from different groups. *P < 0.05 compared to group 8:00 or 4:00. #P < 0.05 compared to group 16:00, 20:00 or 24:00 (LSD).

Figure 4. Influence of dosing times on tEGFR, pEGFR, tERK1/2, and pERK1/2 protein expression in tumor masses. A. Western blot analysis of β-actin, tEGFR and pEGFR protein expression in the tumor. B. Western blot analysis of β-actin, tERK1/2, and pERK1/2 protein expression. C. Relative pEGFR protein expression in the tumor tissues after gefitinib (100 mg/kg) administration. D. Relative pERK1/2 protein expression in the tumor tissues from various groups treated by gefitinib (100 mg/kg) at different time points. *P < 0.05 compared to group 16:00 or 20:00, **P < 0.01 compared to the Model group (ANOVA).
Chronopharmacodynamics of gefitinib-based anti-cancer effect

Influence of gefitinib dosing times on pEGFR and pERK1/2 protein levels

As shown in Figure 4A, the pEGFR protein level in groups 8:00 and 4:00 was significantly lower when compared with that in the Model group, groups 16:00 and 20:00 (P < 0.05, LSD). The phospho-ERK1/2 protein level was also measured (Figure 4B). It was found that pERK1/2 protein level in groups 16:00 and 20:00 was significantly higher than that in groups 8:00 and 4:00 (P < 0.05, LSD).

Influence of gefitinib dosing times on Lewis lung carcinoma cells apoptosis

Now that the anti-tumor effect of gefitinib was distinct when given at various time points, we mainly observed apoptotic level between group 8:00 and group 16:00. As shown in Figure 5, the expression of bax, a pro-apoptotic protein, was increased in group 8:00 compared with the group 16:00. Conversely, bcl-2, a anti-apoptotic protein was significantly decreased (P < 0.05, ANOVA). Also, the TUNEL assay results...
were in accordance the former. Few TUNEL-positive cells were detected in the group 16:00, while TUNEL-positive cells increased dramatically in group 8:00 (18.32% and 43.65%, respectively).

Discussion

As a small molecular-targeted drug, gefitinib has been used for the treatment of advanced NSCLC, and its clinical efficacy has been improved by many researches on molecular biology, especially of cancer-related genes and proteins. Gefitinib is effective in treating NSCLC because it can reversibly and competitively inhibit the binding of adenosine triphosphate (ATP) to the phosphate-binding loop of the ATP site in the intracellular domain of EGFR. By inhibiting the binding of ATP to EGFR, the drug restrains auto-phosphorylation and the activation of downstream signaling pathway further, leading to the inhibition of cell proliferation and inducing apoptosis in NSCLC.

It was demonstrated in this study that the growth of Lewis lung carcinoma inoculated into C57BL/6 mice was inhibited by gefitinib and that the efficacy and adverse reactions of the agent varied with its different dosing time points. After three weeks of administration of gefitinib at certain time points, the tumor volume exhibited significant differences. The tumor sizes in group 8:00 were much smaller than those in groups 16:00, 20:00, and 24:00 ($P$ < 0.01, LSD). The tumor inhibition rate in group 8:00 was significantly higher than that in groups 16:00 and 20:00 (44.12% vs. 14.15% and 22.43%, $P$ < 0.05; Table 2), suggesting that administration of gefitinib at 8:00 can exert its maximum efficacy to inhibit tumor growth. In addition, 4:00 might be another proper time for administering gefitinib. Meanwhile, the tumor tissues in various experimental groups were analyzed by scanning electron microscopy. Morphological analysis about the cells by SEM revealed that the impairment induced by gefitinib to the tumor cells was much severer when the drug was given at 8:00 (Figure 1Bb), with irregular distribution and abnormal deformation. Furthermore, administration of gefitinib at 8:00 can promote tumor cells apoptosis more heavily than at 16:00 (Figure 5). These results collectively suggested that dosing gefitinib in the morning might be more effective.

ABCG2 (ATP-binding cassette sub-family G member 2), a plasma glycoprotein, provides physiological protection against xenobiotics, influences bio-distribution of drugs, and confers multidrug resistance to cancer cells. The accumulation of ABCG2 is in favor of the production of acquired resistance to gefitinib [26]. As over-expression of ABCG2 is a predictor for ill efficacy of gefitinib treatment [27], the ABCG2 expression in solid tumor was measured. The mRNA expressions of ABCG2 in groups 20:00 and 24:00 were extremely high (Figure 3B), suggesting that 8:00 might be suitable for administration of gefitinib without generating acquired drug resistance easily. In addition, the high mRNA expression of ABCG2, a main transport protein, between 20:00 and 24:00 indicates that the metabolism of gefitinib might be faster with short mean residence time (MRT), which wasn’t beneficial to exert its best efficacy.

MMP-9 (matrix metalloproteinase-9), a member of the MMP family, plays a crucial role in degrading type IV collagen fibers and the extracellular matrix, which is closely related to metastasis and invasiveness [28]. MMP-9 may act as underlying prognostic and therapeutic markers in lung cancer, and high expression of MMP-9 means poor prognosis and low survival rate [29]. Hence, the mRNA expression of MMP-9 was determined to compare the influence of gefitinib on the solid tumors in each group. The mRNA expression of MMP-9 in groups 16:00 and 20:00 was increased by 3.20 and 3.32 folds when compared to groups 8:00 (Figure 3C), indicating that administration of gefitinib at 8:00 might result in better prognosis and higher survival rate.

Although typical adverse reactions induced by cytotoxic chemotherapy, such as hematological side effects, can be avoided when gefitinib is applied, cutaneous toxicities caused by gefitinib are still there, which directly affects treatment compliance and impinge on life quality of the patients [30, 31]. Rashes, one major result of cutaneous toxicities, can’t be ignored, although it poses no threat on the life. Observation of skin tissues by SEM indicates that administration of gefitinib at 8:00 might result in better prognosis and higher survival rate.
correlated to serum TNF-α and IL-6 levels [32]. Both TNF-α and IL-6 levels were determined in our study to estimate the impact of gefitinib on rashes. The TNF-α and IL-6 levels in various groups were in accordance with the results of skin tissues observed by SEM. The results indicate that more TNF-α and IL-6 were secreted at 16:00 and 24:00 than at 8:00 and 4:00 (Figure 2), hinting that cutaneous toxicities might be relatively decreased at these two time points.

Interleukin-6 (IL-6), a cytokine featuring pleiotropic activity, contributes to host defense against many diseases. IL-6 plays a significant role in the gastrointestinal tract, and is closely related to colorectal cancer [33]. In the gastrointestinal tract disorders, particularly diarrhea, the plasma level of IL-6 is elevated to modulate biological response to the disease [34]. Therefore, the IL-6 production in the tumor-bearing mice was detected to explore the injury to the gastrointestinal tract caused by gefitinib. The results suggest that the agent might have a weaker influence on the gastrointestinal tract when administered at 8:00.

At present the mechanisms of chronochemotherapy about gefitinib are still unclear. The target of gefitinib is EGFR and gefitinib can suppress the tumor growth by inhibiting EGFR auto-phosphorylation to block the downstream signal transduction. RAF, RAS and ERK1/2 are the downstream factors of EGFR signaling pathway. Some researches [35, 36] have reported ERK1/2 signal pathway is closely related to lung adenocarcinoma and plays a critical role in tumor cell proliferation. Based on the related findings, we investigated whether the EGFR-ERK signaling pathway was sensitive to the small molecular target TKI gefitinib. In this study, the mRNA expression of EGFR was found to have no significant differences (Figure 3A) because it was over-expression in the tumor. However, the proteins p-EGFR and p-ERK1/2 were found to exhibit circadian rhythm on different time points. The p-EGFR and p-ERK1/2 protein levels in groups 8:00 and 4:00 were significantly lower when compared with the Model, groups 16:00, and 20:00 (Figure 4), indicating better inhibition can be achieved to the EGFR signaling through EGFR-RAF-RAS-ERK1/2 pathway when gefitinib was administered at 8:00 and 4:00. Hence, it can be concluded the mechanism of chronochemotherapy of gefitinib might be related to the EGFR-RAS-RAF-ERK1/2 pathway.

Some shortcomings existed in our experiment. For example, the mouse model of Lewis lung carcinoma cells wasn’t consummate for lack of experiments with lung cancer cell line with mutant EGFR. However, this part of research on a mouse model mutant target is being in progress. Secondly, the interstitial pneumonia was not monitored with an effective method. The interstitial pneumonia is a serious and lethal adverse reaction [37, 38], with a reported incidence of 4-6% in Japan and 0.3% in the USA among such parents [39]. Moreover, because it was difficult for us to observe the occurrence of rashes and diarrhea in the tumor bearing mice, we only determined the relevant cytokines to estimate the injuries to the skin and the gastrointestinal tract. Therefore, we carried out morphological analysis of skin cells by SEM in combination with determination of cytokines, TNF-α, and IL-6, to explore its cutaneous toxicities. However, our results are of great significance as a preliminary exploration in the field of small molecular targeted drugs.

In conclusion, this finding of present study reveals, for the first time, that the efficacy and toxicities of gefitinib vary with its dosing time during a day. Moreover, the time-dependent change in the sensitivity of Lewis lung cancer cells may be related to the EGFR-RAS-RAF-ERK1/2 signaling pathway. The time factor should be taken into account when gefitinib is clinically applied.

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Mingchun Li, Department of Pharmacy, 401 Hospital of Chinese People’s Liberation Army, 22 Min-Jiang Road, Qingdao 266071, Shandong, China. Tel: +86-532-51870086; Fax: +86-532-51872904; E-mail: lmc401y@163.com

References


[25] Shao W, Wang W, Xiong XG, Cao C, Yan TD, 
Chen G, Chen H, Yin W, Liu J, Gu Y, Mo M and 
He J. Prognostic impact of MMP-2 and MMP-9 
expression in pathologic stage IA non-small 
cell lung cancer. J Surg Oncol 2011; 104: 841- 
846.

G, Nemet K, Ozvég-Laczka C, Keri G, Orfi L, 
Szakacs G, Settleman J, Varadi A and Sarkadi 
B. Interaction of the EGFR inhibitors gefitinib, 
vandetanib, peltinib and neratinib with the 
ABCG2 multidrug transporter: implications for 
the emergence and reversal of cancer drug re 
sistance. Biochem Pharmacol 2012; 84: 260- 
267.

[27] Chen YJ, Huang WC, Wei YL, Hsu SC, Yuan P, 
Lin HY, Wistuba, Il, Lee JJ, Yen CJ, Su WC, 
Chang KY, Chang WC, Chou TC, Chou CK, Tsai 
CH and Hung MC. Elevated BCRP/ABCG2 ex 
pression confers acquired resistance to gefi 
tinib in wild-type EGFR-expressing cells. PLoS 
One 2011; 6: e21428.

Andrographolide inhibits the activation of NF- 
kappaB and MMP-9 activity in H3255 lung 

[29] Zheng S, Chang Y, Hodges KB, Sun Y, Ma 
X, Xue Y, Williamson SR, Lopez-Beltran A, 
Montironi R and Cheng L. Expression of KISS1 
and MMP-9 in non-small cell lung cancer and 
their relations to metastasis and survival. 

McGuinn WD Jr, Morse D, Abraham S, Rahman 
A, Liang C, Lostritto R, Baird A and Pazdur R. 
United States Food and Drug Administration 
Drug Approval summary: Gefitinib (ZD1839; 
Iressa) tablets. Clin Cancer Res 2004; 10: 
1212-1218.

[31] Lee KH, Lee KY, Jeon YJ, Jung MH, Son C, 
Lee MK, Ryu JS, Yang SH, Lee JC, Kim YC and 
Kim SY. Gefitinib in Selected Patients with Pre 
Treated Non-Small-Cell Lung Cancer: Results 
from a Phase IV, Multicenter, Non-Randomized 
Study (SELINE). Tuberc Respir Dis (Seoul) 

[32] Chen XX, Sun H, Zhang L. Preliminary study of 
immunology mechanism of erlotinib-induced 
skin rash. Tumor 2011; 6: 542-545.

[33] Groblewska M, Mroczko B, Wereszczynska- 
Siemiatkowska U, Kedra B, Lukaszewicz M, 
Baniukiewicz A and Szmitkowski M. Serum in 
terleukin 6 (IL-6) and C-reactive protein (CRP) 
levels in colorectal adenoma and cancer pa 
1428.

[34] O’Malley D, Dinan TG and Cryan JF. Interleukin-6 
modulates colonic transepithelial ion trans 
port in the stress-sensitive wistar kyoto rat. 

IA, Qin X, Li L and Chen L. ERK1/2 mediates 
lung adenocarcinoma cell proliferation and au 
tophagy induced by apelin-13. Acta Biochim 
Biophys Sin (Shanghai) 2014; 46: 100-111.

[EGFR-ERK signaling pathway down-regulates 
miRNA-145 in lung cancer cells]. Zhonghua 

[37] Chang SC, Chang CY, Chang SJ, Yuan MK, Lai 
YC, Liu YC, Chen CY, Kuo LC and Yu CJ. Gefitinib 
related interstitial lung disease in Taiwanese 
patients with non-small-cell lung cancer. Clin 

[38] Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue 
Y, Kimura Y, Ebina M, Kikuchi T, Moriya T and 
Nukiwa T. Severe acute interstitial pneumonia 

[39] Murashige N, Tanimoto T and Oshima Y. Inter 
2010; 363: 1578-1579.